Prognostic heterogeneity of adult B‐cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/<i>TCF3‐PBX1</i> treated with measurable residual disease‐oriented protocols
Jordi Ribera(Josep Carreras Leukaemia Research Institute), Marta Cervera(Hospital Universitari Joan XXIII de Tarragona), Mireia Morgades(Josep Carreras Leukaemia Research Institute), Irene García‐Cadenas(Hospital de Sant Pau), Rosa Coll(Hospital Universitari de Girona Doctor Josep Trueta), Cristina Gil(Hospital General Universitario de Alicante Doctor Balmis), Pere Barba(Universitat Autònoma de Barcelona), Isabel Granada(Josep Carreras Leukaemia Research Institute), Esperanza Such(Leitat Technological Center), Dolors Costa(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Juana Ciudad(Universidad de Salamanca), Rosa Ayala(Hospital Universitario 12 De Octubre), José González‐Campos(Hospital Universitario Virgen del Rocío), Alberto Órfão(Universidad de Salamanca), Marı́a José Calasanz(Navarre Institute of Health Research), Teresa González(Instituto de Investigación Biomédica de Salamanca), Santiago Mercadal(Huntsman Cancer Institute), Arancha Bermúdez(Marqués de Valdecilla University Hospital)
Cited by 7
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
Non-coding recurrent mutations in chronic lymphocytic leukaemia
|Nature|2015|851
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
|Proceedings of the National Academy of Sciences|2013|519